Veterinary Biologics Companies

The global veterinary biologics market is projected to reach USD 3.51 billion by 2030 from USD 2.72 billion in 2025, at a CAGR of 5.2%. Growth in this market is mainly driven by the rising number of companion animals and pet ownership, along with increasing concerns about chronic diseases in animals. There is greater adoption of pet insurance and higher spending on animal healthcare, supported by awareness campaigns from the government and animal welfare organizations, which further boost the market growth.

The leading companies in the veterinary biologics market include Zoetis (US), Elanco (US), and Merck & Co., Inc. (US). These companies continuously develop new products and adopt growth strategies such as partnerships and expansion to increase their market presence.

• In May 2023, Zoetis Services LLC received FDA approval for its Librela (bedinvetmab), the first and only once-monthly injectable monoclonal antibody targeting nerve growth factor (NGF) for managing osteoarthritis pain in dogs, providing long-term mobility and quality-of-life benefits validated in clinical trials involving client-owned pets.
• In October 2023, Merck & Co., Inc. launched its Gilvetmab (gil-VET-mab), a caninized monoclonal antibody for oncology-practicing veterinary specialists across the US. Gilvetmab previously received conditional license approval from the US Department of Agriculture (USDA) Center.  

To know about the assumptions considered for the study download the pdf brochure

Zoetis (US)

Zoetis discovers, develops, manufactures, and markets biologics and medicines for livestock and companion animals. The company operates through three segments: Companion Animals, Livestock, and Contract Manufacturing & Human Health. It offers dermatology products for animals through both the Companion Animals and Livestock segments. Zoetis operates in 70 countries, and its products are sold in over 120 countries via its distribution networks. Some key subsidiaries include Alpharma Animal Health Company (US), Fort Dodge Asia Exports, Inc. (US), and Jilin Pfizer Guoyuan Animal Health Co., Ltd (China). The company also heavily invests in product launches and development. For example, in October 2023, Zoetis launched Librela (bedinvetmab injection) in the US, its first-ever injectable monoclonal antibody for treating osteoarthritis pain in dogs. Librela targets nerve growth factor (NGF) to significantly improve dog mobility and comfort, offering an innovative alternative to daily NSAID therapy.

Elanco (US)

Elanco is a global leader in animal health and is committed to providing innovative products and services that prevent and treat diseases in farm animals and pets. With a portfolio of about 200 brands, Elanco offers solutions for various species, including dogs, cats, cattle, poultry, swine, sheep, and fish under farm animal care. The company mainly operates through one business segment but organizes its sales and operations into three main categories: pet health, farm animals, and contract manufacturing. A significant focus for Elanco is monoclonal antibody (mAb) therapies. In 2023, Elanco introduced the world’s first USDA conditionally approved mAb treatment for canine parvovirus. Through ongoing investment in mAb research and development, as well as expanded biologics manufacturing, Elanco is progressing its pipeline for future antibody-based therapies. Additionally, the company’s presence in over 90 countries plays a strong role in the animal health market.

Merck & Co., Inc. (US)

Merck & Co., Inc. is a leading global healthcare company, providing innovative solutions such as prescription drugs, vaccines, biologic therapies, and products for animal health. The company operates through two main divisions: Pharmaceuticals and Animal Health. Its Animal Health division offers monoclonal antibody therapies for companion animals. Merck has a presence in over 140 countries and owns 25 manufacturing facilities across the Americas, Europe, and the Asia Pacific. Its strong R&D network includes 16 research centers located in the US, Spain, Germany, Norway, South Africa, India, Australia, Singapore, and Japan. For example, in May 2025, Merck Animal Health expanded its manufacturing and R&D facilities in De Soto, Kansas, with an investment of USD 895 million. This strategic expansion aims to increase production capacity and drive innovation, especially in biologics and vaccine development, including monoclonal antibody therapies.

Market Ranking

The global veterinary biologics market is competitive, with the top players being Zoetis (US), Elanco (US), and Merck & Co., Inc. (US). The competition among these leading companies is intense, and most focus on forming partnerships to maintain a stable market share. The market is controlled by major players with a strong global presence and well-developed supply and distribution networks in regions like North America and Europe.

Related Reports:

Veterinary Biologics Market by Product (Monoclonal Antibodies, Diagnostic Kits, Immunoglobulins & Antitoxins), RoA (Injectable, Oral), Application (Infectious Disease Prevention, Dermatology, Pain Management), Animal, End User - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com